Delay In The Clinical Trial Publishing Affects US

Clinical trials run across the world in order to decide the efficiency and safety of the clinical trial before the drug enters into the market. Clinical trials run for a long period of time and unpublished data in the clinical trials results either in over estimation or underestimation about the efficiency of the drug that is processed in the clinical trial. The trial data published in the peer reviewed journals found to be fewer than half due to many reasons like rejection of the publications.

Clinical research discovers a medicine to treat particular diseases under uncertainty and the clinical trials confirm the efficiency of the drug. It is not that every drug that reaches the clinical trial phase is success. They may end up in failures too. If the clinical trial data is kept unpublished at the end of each and every phase, it may lead to costly mistake again. Most of the investigators depend on the peer reviewed journals for the clinical trial investigation. Lack of accessibility to the clinical trial data may evoke to investigate on the same tested formulation which leads to costly mistake again. More over this unpublished data of the clinical trials can even harm the patients in the ignorance of the risk associated with the drug.